

Claims

In the claims, please amend the claims as follows:

1. – 10. (Canceled).

11. (Currently Amended) An inhalable solid pharmaceutical formulation comprising

- (a) 4-{{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and
- or a pharmaceutically acceptable salt thereof;
- (b) lactose and
- (c) magnesium stearate.

12. (Previously Presented) An inhalable solid pharmaceutical formulation as claimed in claim 11 wherein the magnesium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

13. (Canceled).

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).

18. (Withdrawn) A method for treating asthma, chronic obstructive pulmonary disease (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in claim 11.

19. (Withdrawn) A method of preparing the solid pharmaceutical formulation of claim 11 comprising combining in one or more steps:

(a) 4-[(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof

(b) lactose and

(c) magnesium stearate.

20. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein the active ingredient substance 4-[(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol or pharmaceutically acceptable salt thereof is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

21. (Canceled).

22. (Canceled).

23. (Canceled).

24. (Canceled).

25. (Canceled).

26. (Withdrawn and New) A method of inhibiting chemical degradation of 4-[(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof in a formulation comprising a lactose carrier, said method comprises:

combining

a) said 4-((1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof

b) said lactose, and

c) magnesium stearate.

27. (Withdrawn and New) The method of claim 26, wherein the magnesium stearate is combined in an amount of from 0.1 to 20% w/w based on the total weight of the formulation.

28. (Withdrawn and New) The method of claim 19, wherein the 4-((1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof is combined in an amount of from 0.01% to 50% w/w based on the total weight of the formulation.